GRCE Earnings & Financial Statements
Grace Therapeutics, Inc.
$2.04
-$0.06(-2.86%)
32
Overall
60
Value
10
Tech
26
Quality
Market Cap
$42.91M
Volume
52.59K
52W Range
$1.79 - $5.18
Target Price
$6.00
GRCE earnings and financial statements: Grace Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
GRCE Annual Financial Statements
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating income | -$11.08M | -$16.68M | -$12.85M | -$18.25M | -$15.34M |
| EBITDA | -$9.49M | -$12.76M | -$14.67M | -$51.85M | -$15.34M |
| Net income | -$7.79M | -$15.97M | -$12.85M | -$42.43M | -$9.22M |
| EPS (diluted) | $-0.47 | $-0.79 | $-1.35 | $-0.95 | $-0.27 |
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total assets | $66.65M | $71.99M | $73.30M | $79.12M | $128.62M |
| Total liabilities | $2.76M | $5.38M | $11.56M | $11.17M | $20.35M |
| Shareholders’ equity | $63.90M | $66.61M | $61.74M | $67.95M | $108.27M |
| Cash and equivalents | $16.98M | $22.13M | $23.00M | $27.88M | $30.34M |
| Long-term debt | - | - | - | $410.0K | $191.0K |
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating cash flow | -$8.87M | -$14.90M | -$12.33M | -$15.91M | -$17.23M |
| Free cash flow | -$8.87M | -$14.90M | - | - | -$17.23M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GRCE | $2.04 | -2.9% | 52.59K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Grace Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW